Azenosertib clinical trials
Also written ZN-c3 and KP-2638.
How each study uses azenosertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the azenosertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 6
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (7) · OHSU Knight Cancer Institute (2) · National Cancer Institute (NCI) (1) · Joyce Liu, MD (1) · Filipa Lynce, MD (1) · K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (1) · Zentera Therapeutics HK Limited (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Cobimetinib (1) · Olaparib (1) · Onvansertib (1) · AZD5305 (1) · Tremelimumab (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test azenosertib.
- Dec 2026A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerPhase 2 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Jan 2027Azenosertib in Uterine Serous Carcinoma: Biomarker StudyPhase 2 · Joyce Liu, MD
- Jun 2027Targeted Pathway Inhibition in Patients With Pancreatic CancerEarly Phase 1 · OHSU Knight Cancer Institute
- Jul 2027Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsPhase 1 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses azenosertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein ExpressionRecruitingPhase 3K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT07546500Written as Azenosertib
- A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05128825Written as azenosertib
- Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT06364410Written as Azenosertib
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690Written as Azenosertib
- Azenosertib in Uterine Serous Carcinoma: Biomarker StudyRecruitingPhase 2Joyce Liu, MDNCT06369155Written as Azenosertib
- ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCTerminatedPhase 1Filipa Lynce, MDNCT06351332Written as Azenosertib
- A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With OsteosarcomaCompletedPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04833582Written as Azenosertib
- A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompletedPhase 1/2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05198804Written as Azenosertib
- A Study of Azenosertib (ZN-c3) in Participants With Solid TumorsCompletedPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04158336Written as Azenosertib
- A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaCompletedPhase 2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04814108Written as Azenosertib
- ZN-c3 in Adult Participants With Metastatic Colorectal CancerTerminatedPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05743036Written as ZN-c3
- Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)TerminatedPhase 1/2K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.NCT05682170Written as ZN-c3
- Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid TumorsWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05431582Written as ZN-c3
- ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian CancerWithdrawnEarly Phase 1OHSU Knight Cancer InstituteNCT05368506Written as Wee1 Inhibitor ZN-c3
- A Phase 1b Study of ZN-c3 in Chinese SubjectsStatus unknownPhase 1Zentera Therapeutics HK LimitedNCT04972422Written as ZN-c3
Given beside what is tested · 1 — azenosertib is usual care or a partner of the new treatment
Codes
What other systems call azenosertib · ClinicalTrials.gg INT015873
- UNII (FDA) 9J13XU96Z1AZENOSERTIBOne source FDA
- NCI Thesaurus C167064AzenosertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9J13XU96Z1 | AZENOSERTIB | One source FDA |
| NCI Thesaurus | C167064 | Azenosertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.